GO:0032435 negative regulation of proteasomal ubiquitin-dependent protein catabolic process: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032435 describes any process that stops, prevents, or reduces the frequency, rate, or extent of ubiquitin-dependent protein breakdown by the proteasome.
• Negative regulation can occur by deubiquitination, substrate sequestration, inhibition of ubiquitin ligases, or direct modulation of proteasome activity.
• Key negative regulators include Cbl-family ligases, FBXO11, KBTBD11, ODF2, and CDC48A/PUX10, which control substrates such as CIITA, ENO1, CP110, and peroxisomal proteins.
• Dysregulation of this process contributes to cancer, immune disorders, ciliopathies, and metabolic diseases.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of negative regulators in this pathway.
• EDITGENE provides end-to-end CRISPR services, including library screening and bioinformatics, to study GO:0032435-related genes.
Description
The ubiquitin-proteasome system (UPS) is the major pathway for selective protein degradation in eukaryotes, controlling processes as diverse as cell cycle progression, signal transduction, and immune response. Within this system, GO:0032435 (negative regulation of proteasomal ubiquitin-dependent protein catabolic process) encompasses all mechanisms that attenuate the ubiquitination or proteasomal breakdown of specific protein substrates. This regulation is essential for maintaining protein homeostasis and preventing inappropriate degradation of key regulatory proteins. Researchers study GO:0032435 to understand how cells fine-tune protein stability, how pathogens and cancer cells exploit these mechanisms, and how to target them therapeutically. The term is defined in QuickGO as any process that stops, prevents, or reduces the frequency, rate or extent of the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, and mediated by the proteasome.
negative regulation of proteasomal ubiquitin-dependent protein catabolic process At A Glance
| GO ID | GO:0032435 |
|---|---|
| GO term | negative regulation of proteasomal ubiquitin-dependent protein catabolic process |
| Ontology | biological_process |
| Synonym | down regulation of proteasomal ubiquitin-dependent protein catabolic process; down-regulation of proteasomal ubiquitin-dependent protein catabolic process; downregulation of proteasomal ubiquitin-dependent protein catabolic process; inhibition of proteasomal ubiquitin-dependent protein catabolic process |
| Major function | Attenuation of ubiquitin-dependent protein degradation by the proteasome |
| Related processes | Protein homeostasis, signal transduction, immune regulation, cell cycle control |
| Key regulators | Cbl-family ligases, FBXO11, KBTBD11, ODF2, CDC48A/PUX10, deubiquitinases |
| Disease relevance | Cancer, immune disorders, ciliopathies, metabolic diseases |
What Is GO:0032435?
GO:0032435 refers to biological processes that negatively regulate the ubiquitin-dependent degradation of proteins by the proteasome. This includes inhibition of ubiquitin ligases, promotion of deubiquitination, sequestration of substrates, or direct interference with proteasome activity. The term is a child of negative regulation of proteasomal protein catabolic process and is distinct from positive regulation (GO:0032436).
Why Is negative regulation of proteasomal ubiquitin-dependent protein catabolic process Important in Cell Biology?
Negative regulation of proteasomal ubiquitin-dependent protein catabolic process is critical for preventing premature or excessive degradation of regulatory proteins, thereby maintaining cellular homeostasis and enabling appropriate responses to environmental cues. Its dysregulation is implicated in cancer, where substrates such as ENO1 and CIITA are protected from degradation, and in immune disorders where MHC class II expression is altered. Understanding this process provides insights into fundamental cell biology and offers therapeutic targets for a range of diseases.
• Controls the stability of oncoproteins and tumor suppressors, influencing cancer progression.
• Regulates immune responses by modulating MHC class II expression through CIITA stability.
• Affects ciliogenesis by controlling CP110 levels at centrioles.
• Modulates growth hormone receptor signaling and endocrine function.
• Influences peroxisomal protein turnover in plants, impacting metabolic pathways.
• Plays a role in NFκB signaling by regulating IκB degradation.
• Regulates protein tyrosine kinase signaling through Cbl-family ligases.
• Contributes to petite-negativity in fission yeast, affecting mitochondrial function.
• Provides targets for therapeutic intervention in cancer and immune diseases.
• Essential for understanding proteostasis in health and disease.
What Happens During negative regulation of proteasomal ubiquitin-dependent protein catabolic process?
Substrate Recognition and Ubiquitin Ligase Inhibition
In simple terms: Cells can stop proteins from being tagged for destruction by blocking the enzymes that add ubiquitin tags.
Negative regulation often begins with inhibition or downregulation of E3 ubiquitin ligases, preventing substrate ubiquitination. For example, Cbl-family ligases are themselves regulated by ubiquitination, which can attenuate their activity toward protein tyrosine kinases. Similarly, FBXO11 acts as a negative regulator of MHC class II by targeting CIITA for degradation, but its own activity can be modulated. In Arabidopsis, PUX10 and CDC48A regulate the degradation of peroxisomal proteins, demonstrating that negative regulation can occur at the level of substrate extraction.
Deubiquitination and Substrate Stabilization
In simple terms: Deubiquitinating enzymes remove ubiquitin tags from proteins, saving them from degradation.
Deubiquitinases (DUBs) counteract ubiquitination by cleaving ubiquitin chains from substrates, thereby stabilizing them. This is a direct mechanism of negative regulation of proteasomal degradation. For instance, in the NFκB pathway, DUBs such as A20 remove ubiquitin from IκB, preventing its degradation and inhibiting NFκB activation. Similarly, ODF2 negatively regulates CP110 levels at centrioles by a mechanism that may involve protection from ubiquitination.
Sequestration and Compartmentalization
In simple terms: Proteins can be kept away from the proteasome by being stored in specific cellular locations.
Substrates can be sequestered away from the proteasome or from ubiquitination machinery. For example, KBTBD11 suppresses hepatocellular carcinoma by targeting ENO1-mediated glycolysis, potentially by altering ENO1 stability or localization. In fission yeast, proteasome regulation of petite-negativity involves compartmentalization of degradation machinery. This spatial control ensures that proteins are degraded only when and where appropriate.
Direct Proteasome Inhibition
In simple terms: Some molecules can directly block the proteasome's ability to cut proteins.
Direct inhibition of proteasome catalytic activity is another mode of negative regulation. While less common for specific substrates, it can occur through regulatory proteins that bind to the proteasome. In plants, CDC48A and PUX10 regulate the extraction of peroxisomal proteins, which may involve modulation of proteasome access. This mechanism is crucial for preventing excessive degradation under stress conditions.
Regulation of Negative Regulators
In simple terms: The brakes on protein degradation can themselves be controlled, adding layers of regulation.
Negative regulators are subject to regulation by ubiquitination, phosphorylation, and other modifications. For example, Cbl-family ligases are regulated by autoubiquitination and deubiquitination. FBXO11 activity can be modulated by cellular signals. This ensures that negative regulation is dynamic and responsive to cellular needs.
Key Genes Involved in GO:0032435 negative regulation of proteasomal ubiquitin-dependent protein catabolic process
The following genes and proteins are key players in negative regulation of proteasomal ubiquitin-dependent protein catabolic process, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CBL | E3 ubiquitin ligase; regulates tyrosine kinases | Negative regulation of RTK signaling |
| FBXO11 | Targets CIITA for degradation | Negative regulator of MHC class II |
| KBTBD11 | Suppresses HCC by targeting ENO1 | Tumor suppressor in liver cancer |
| ODF2 | Negatively regulates CP110 at centrioles | Controls ciliogenesis |
| CDC48A | Regulates peroxisomal protein degradation | Plant peroxisome function |
| PUX10 | UBA domain protein; regulates CDC48A | Plant peroxisomal degradation |
| A20 (TNFAIP3) | Deubiquitinase; removes ubiquitin from IκB | NFκB signaling |
| CIITA | Substrate of FBXO11; MHC class II transactivator | Immune regulation |
| ENO1 | Substrate of KBTBD11; glycolytic enzyme | Cancer metabolism |
| CP110 | Substrate of ODF2; centriolar protein | Ciliogenesis |
| GHR | Growth hormone receptor; regulated by ubiquitination | Endocrine signaling |
| IκB | Inhibitor of NFκB; degraded via ubiquitin-proteasome | Inflammation |
| Protein tyrosine kinases | Substrates of Cbl ligases | Signal transduction |
| Peroxisomal proteins | Substrates of CDC48A/PUX10 | Plant metabolism |
| Petite-negativity factors | Regulated by proteasome in fission yeast | Mitochondrial function |
How Is negative regulation of proteasomal ubiquitin-dependent protein catabolic process Regulated?
Negative regulation of proteasomal ubiquitin-dependent protein catabolic process is itself regulated at multiple levels. Deubiquitinases such as A20 are induced by NFκB signaling, creating a negative feedback loop. Cbl-family ligases are regulated by phosphorylation and autoubiquitination. In plants, CDC48A and PUX10 are regulated by ubiquitin-associated domains. Additionally, proteasome activity can be modulated by post-translational modifications of proteasome subunits.
negative regulation of proteasomal ubiquitin-dependent protein catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KBTBD11 | Hepatocellular carcinoma | KO and overexpression in HCC cell lines |
| FBXO11 | Autoimmune disorders, MHC class II regulation | KO and point mutation in immune cells |
| ODF2 | Ciliopathies | KO and knock-in in ciliated cells |
| A20 (TNFAIP3) | Autoinflammatory diseases | KO and overexpression in macrophages |
| CBL | Cancer, immune dysregulation | Point mutation and KO in hematopoietic cells |
Cancer
Dysregulation of negative regulation of proteasomal degradation contributes to cancer. KBTBD11 suppresses hepatocellular carcinoma by targeting ENO1-mediated glycolysis, and loss of KBTBD11 leads to ENO1 accumulation and enhanced glycolysis. FBXO11 negatively regulates MHC class II, and its dysfunction may affect immune surveillance. Targeting these negative regulators could offer therapeutic strategies.
Immune Disorders
FBXO11 controls CIITA stability, thereby regulating MHC class II expression. Impaired FBXO11 function leads to increased CIITA and MHC class II, which is associated with autoimmune conditions. Similarly, A20 (TNFAIP3) negatively regulates NFκB by deubiquitinating IκB, and its mutations are linked to autoimmune diseases.
Ciliopathies
ODF2 negatively regulates CP110 at centrioles, controlling primary cilia biogenesis. Disruption of this regulation can lead to ciliopathies characterized by defects in cilia formation.
Metabolic and Endocrine Disorders
Negative regulation of growth hormone receptor signaling involves ubiquitin-mediated degradation, and its dysregulation may contribute to growth disorders. In plants, CDC48A and PUX10 regulate peroxisomal protein degradation, affecting lipid metabolism.
From negative regulation of proteasomal ubiquitin-dependent protein catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does KBTBD11 negatively regulate ENO1 degradation? | KBTBD11 KO and overexpression in HCC cells |
| How does FBXO11 control CIITA stability? | FBXO11 KO and point mutation in B cells |
| What is the role of ODF2 in CP110 regulation? | ODF2 KO and tagged knock-in in RPE1 cells |
| How does A20 deubiquitinate IκB? | A20 KO and overexpression in HEK293T |
| Does Cbl regulate tyrosine kinase stability? | Cbl KO and point mutation in fibroblasts |
| How do CDC48A and PUX10 regulate peroxisomal proteins? | CDC48A/PUX10 KO in Arabidopsis |
How to Study the negative regulation of proteasomal ubiquitin-dependent protein catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Mass spectrometry | Ubiquitinated proteins and interactors | Identify substrates of negative regulators |
| RNA-seq | Transcriptional changes | Measure downstream effects of stabilized proteins |
| Western blot | Protein stability and ubiquitination | Validate substrate degradation |
| Immunofluorescence | Subcellular localization | Track substrate sequestration |
| In vitro ubiquitination | Enzymatic activity | Measure ligase or DUB activity |
| CRISPR screening | Gene function in degradation | Identify novel negative regulators |
| Proteasome activity assay | Proteolytic activity | Assess direct proteasome inhibition |
Proteomics and Ubiquitinome Analysis
Mass spectrometry-based proteomics can identify ubiquitinated substrates and changes in protein stability upon modulation of negative regulators. For example, ubiquitinome analysis in KBTBD11 KO cells reveals ENO1 ubiquitination status. Similarly, proteomic profiling of FBXO11 KO cells shows CIITA accumulation.
RNA-seq and Transcriptomics
RNA sequencing measures changes in gene expression resulting from altered protein degradation. In FBXO11 KO cells, MHC class II genes are upregulated due to CIITA stabilization. Transcriptomic analysis of KBTBD11-overexpressing HCC cells reveals metabolic gene changes.
Imaging and Localization Studies
Fluorescence microscopy can visualize substrate localization and stability. ODF2 and CP110 co-localization at centrioles is disrupted upon ODF2 depletion. Live-cell imaging of tagged proteins can track degradation dynamics.
Biochemical Assays
In vitro ubiquitination and deubiquitination assays reconstitute the reactions. A20 deubiquitinase activity on IκB can be measured. Cbl autoubiquitination assays reveal regulation.
How CRISPR Can Be Used to Study GO:0032435 negative regulation of proteasomal ubiquitin-dependent protein catabolic process
Knockout
CRISPR knockout of negative regulators such as KBTBD11, FBXO11, or ODF2 leads to substrate accumulation, revealing their role in degradation. For example, FBXO11 KO increases CIITA and MHC class II expression.
Point Mutation
Point mutations can dissect specific domains required for negative regulation. Mutating the RING domain of Cbl ligases abolishes their E3 activity, affecting substrate degradation. Similarly, mutations in the UBA domain of PUX10 impair peroxisomal protein regulation.
Knock-in
Knock-in of tagged versions (e.g., GFP, HA) allows tracking of endogenous proteins. Tagged ODF2 knock-in enables visualization of CP110 regulation at centrioles. Tagged A20 knock-in facilitates deubiquitinase studies.
Overexpression
Overexpression of negative regulators such as KBTBD11 or FBXO11 enhances substrate degradation, confirming their function. Overexpression of A20 suppresses NFκB signaling by degrading IκB.
How EDITGENE Supports negative regulation of proteasomal ubiquitin-dependent protein catabolic process Research
Researchers studying negative regulation of proteasomal ubiquitin-dependent protein catabolic process-related genes often need to determine whether a candidate gene is causally involved in substrate stabilization or degradation. EDITGENE provides comprehensive CRISPR services to enable such investigations.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of proteasomal ubiquitin-dependent protein catabolic process research.
Frequently Asked Questions About negative regulation of proteasomal ubiquitin-dependent protein catabolic process
What is GO:0032435?
GO:0032435 is a Gene Ontology term for any process that negatively regulates the ubiquitin-dependent degradation of proteins by the proteasome.
What genes are involved in negative regulation of proteasomal ubiquitin-dependent protein catabolic process?
Key genes include CBL, FBXO11, KBTBD11, ODF2, CDC48A, PUX10, and A20 (TNFAIP3).
How does FBXO11 regulate MHC class II?
FBXO11 targets CIITA for ubiquitin-dependent degradation, thereby negatively regulating MHC class II expression.
What is the role of KBTBD11 in cancer?
KBTBD11 suppresses hepatocellular carcinoma by targeting ENO1-mediated glycolysis, acting as a negative regulator of ENO1 stability.
How does ODF2 control ciliogenesis?
ODF2 negatively regulates CP110 levels at centrioles, preventing premature cilia formation.
What is the function of A20 in NFκB signaling?
A20 is a deubiquitinase that removes ubiquitin from IκB, preventing its degradation and inhibiting NFκB activation.
How can CRISPR be used to study GO:0032435?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of negative regulators and their substrates.
What diseases are associated with dysregulation of this process?
Cancer, autoimmune disorders, ciliopathies, and metabolic diseases are linked to altered negative regulation of proteasomal degradation.
What methods are used to study negative regulation of proteasomal degradation?
Proteomics, RNA-seq, imaging, biochemical assays, and CRISPR screens are commonly used.
How does Cbl regulate tyrosine kinases?
Cbl-family ligases ubiquitinate protein tyrosine kinases, but their activity can be negatively regulated by autoubiquitination or deubiquitination.
Conclusion
GO:0032435 encompasses diverse mechanisms that attenuate ubiquitin-dependent proteasomal degradation, protecting key regulatory proteins from destruction. Its dysregulation underlies cancer, immune disorders, and other diseases, making it a rich area for therapeutic targeting. CRISPR-based models are indispensable for dissecting these pathways and identifying new drug targets.
References
- 1. Liu Y et al.. 2025. KBTBD11 suppresses hepatocellular carcinoma by targeting ENO1-mediated glycolysis.. J Transl Med 23(1):1087 PMID: 41088215
- 2. Amberg KL et al.. 2025. Proteasome regulation of petite-negativity in fission yeast.. BMC Biol 23(1):302 PMID: 41068765
- 3. Xu H et al.. 2015. Ubiquitin-mediated NFκB degradation pathway.. Cell Mol Immunol 12(6):653-5 PMID: 25345807
- 4. Mohapatra B et al.. 2013. Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases.. Biochim Biophys Acta 1833(1):122-39 PMID: 23085373
- 5. Otto M et al.. 2023. ODF2 Negatively Regulates CP110 Levels at the Centrioles/Basal Bodies to Control the Biogenesis of Primary Cilia.. Cells 12(17) PMID: 37681926
- 6. Kasuga Y et al.. 2023. FBXO11 constitutes a major negative regulator of MHC class II through ubiquitin-dependent proteasomal degradation of CIITA.. Proc Natl Acad Sci U S A 120(24):e2218955120 PMID: 37279268
- 7. Flores-Morales A et al.. 2006. Negative regulation of growth hormone receptor signaling.. Mol Endocrinol 20(2):241-53 PMID: 16037128
- 8. Li J et al.. 2026. CDC48A and the ubiquitin-associated domain protein PUX10 regulate the ubiquitin-dependent degradation of peroxisomal proteins in Arabidopsis.. Plant Cell 38(6) PMID: 42203491
